## Peter Ferguson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6383964/publications.pdf

Version: 2024-02-01

304602 233338 2,189 67 22 45 h-index citations g-index papers 69 69 69 3781 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nature Communications, 2019, 10, 3163.	5.8	205
2	Simple Synthesis and Functionalization of Iron Nanoparticles for Magnetic Resonance Imaging. Angewandte Chemie - International Edition, 2011, 50, 4206-4209.	7.2	148
3	Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities. Journal of Pathology, 2019, 247, 539-551.	2.1	142
4	ILC2s and T cells cooperate to ensure maintenance of M2 macrophages for lung immunity against hookworms. Nature Communications, 2015, 6, 6970.	5.8	135
5	Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Annals of Oncology, 2018, 29, 1861-1868.	0.6	135
6	Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. Lancet Oncology, The, 2019, 20, 961-971.	5.1	126
7	Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. Pathology, 2021, 53, 141-156.	0.3	126
8	Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. Nature Communications, 2020, 11, 5259.	5.8	102
9	A self-adjuvanting vaccine induces cytotoxic T lymphocytes that suppress allergy. Nature Chemical Biology, 2014, 10, 943-949.	3.9	70
10	Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. Cancer Cell, 2022, 40, 88-102.e7.	7.7	64
11	Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. Oncolmmunology, 2019, 8, e1537581.	2.1	61
12	Melanoma pathology reporting and staging. Modern Pathology, 2020, 33, 15-24.	2.9	61
13	Hot-injection synthesis of iron/iron oxide core/shell nanoparticles for T2 contrast enhancement in magnetic resonance imaging. Chemical Communications, 2011, 47, 9221.	2.2	58
14	Molecular Genomic Profiling of MelanocyticÂNevi. Journal of Investigative Dermatology, 2019, 139, 1762-1768.	0.3	55
15	Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility. International Journal of Cancer, 2019, 144, 1049-1060.	2.3	54
16	HDAC inhibitors restore BRAFâ€inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma. International Journal of Cancer, 2018, 142, 1926-1937.	2.3	48
17	Vaccination with Irradiated Tumor Cells Pulsed with an Adjuvant That Stimulates NKT Cells Is an Effective Treatment for Glioma. Clinical Cancer Research, 2012, 18, 6446-6459.	3.2	47
18	Significant association of PD-L1 expression with human papillomavirus positivity and its prognostic impact in oropharyngeal cancer. Oral Oncology, 2019, 92, 33-39.	0.8	43

#	Article	lF	Citations
19	Synthesis and Stability of Highly Crystalline and Stable Iron/Iron Oxide Core/Shell Nanoparticles for Biomedical Applications. ChemPlusChem, 2012, 77, 135-140.	1.3	37
20	Pleomorphic giant cell carcinoma of the urinary bladder: an extreme form of tumour deâ€differentiation. Histopathology, 2016, 68, 533-540.	1.6	35
21	Total submission of pelvic lymphadenectomy tissues removed during radical prostatectomy for prostate cancer increases lymph node yield and detection of micrometastases. Histopathology, 2014, 64, 399-404.	1.6	31
22	Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas. Oncotarget, 2019, 10, 930-941.	0.8	31
23	Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence. Nature Cancer, 2020, 1, 197-209.	5.7	30
24	Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma. Cancers, 2020, 12, 3374.	1.7	27
25	Blocking CTLA-4 while priming with a whole cell vaccine reshapes the oligoclonal T cell infiltrate and eradicates tumors in an orthotopic glioma model. Oncolmmunology, 2018, 7, e1376154.	2.1	22
26	î³Î´T Cells in Merkel Cell Carcinomas Have a Proinflammatory Profile Prognostic of Patient Survival. Cancer Immunology Research, 2021, 9, 612-623.	1.6	22
27	Correlation Between Surgical and Histologic Margins in Melanoma Wide Excision Specimens. Annals of Surgical Oncology, 2019, 26, 25-32.	0.7	21
28	The tumour immune landscape and its implications in cutaneous melanoma. Pigment Cell and Melanoma Research, 2021, 34, 529-549.	1.5	21
29	Using Magnetic Resonance Imaging to Evaluate Dendritic Cell-Based Vaccination. PLoS ONE, 2013, 8, e65318.	1.1	17
30	Inter―and intrapatient heterogeneity of indoleamine 2,3â€dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment. Histopathology, 2019, 74, 817-828.	1.6	16
31	Melanoma protective antitumor immunity activated by catalytic DNA. Oncogene, 2018, 37, 5115-5126.	2.6	15
32	Proteins from formalin-fixed paraffin-embedded prostate cancer sections that predict the risk of metastatic disease. Clinical Proteomics, 2015, 12, 24.	1.1	13
33	Pembrolizumab for cutaneous squamous cell carcinoma: Report of a case of inoperable squamous cell carcinoma with complete response to pembrolizumab complicated by granulomatous inflammation. JAAD Case Reports, 2019, 5, 491-494.	0.4	13
34	Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas. Cancer Immunology Research, 2020, 8, 1346-1353.	1.6	13
35	Strongly Magnetic Iron Nanoparticles Improve the Diagnosis of Small Tumours in the Reticuloendothelial System by Magnetic Resonance Imaging. PLoS ONE, 2013, 8, e56572.	1.1	12
36	Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/ $\hat{a}$ Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets. Cancers, 2021, 13, 3186.	1.7	11

3

#	Article	IF	CITATIONS
37	Dermoscopic features and screening strategies for the detection of smallâ€diameter melanomas. Clinical and Experimental Dermatology, 2022, 47, 932-941.	0.6	11
38	Enhancing T cell responses and tumour immunity by vaccination with peptides conjugated to a weak NKT cell agonist. Organic and Biomolecular Chemistry, 2019, 17, 1225-1237.	1.5	10
39	Molecular Profiling of Noncoding Mutations Distinguishes Nevoid Melanomas From Mitotically Active Nevi in Pregnancy. American Journal of Surgical Pathology, 2020, 44, 357-367.	2.1	10
40	Vaccines adjuvanted with an NKT cell agonist induce effective T-cell responses in models of CNS lymphoma. Immunotherapy, 2020, 12, 395-406.	1.0	10
41	Improving diagnostic accuracy for suspicious melanocytic skin lesions: New Australian melanoma clinical practice guidelines stress the importance of clinician/pathologist communication. Australian Journal of General Practice, 2019, 48, 357-362.	0.3	9
42	<i>NRAS</i> and <i>EPHB6</i> mutation rates differ in metastatic melanomas of patients in the North Island versus South Island of New Zealand. Oncotarget, 0, 7, 41017-41030.	0.8	7
43	Primary dermal melanoma: clinical behaviour, prognosis and treatment. European Journal of Surgical Oncology, 2020, 46, 2131-2139.	0.5	5
44	Transplant-associated penile Kaposi sarcoma managed with single agent paclitaxel chemotherapy: a case report. BMC Urology, 2021, 21, 87.	0.6	5
45	Staging of Cutaneous Melanoma. JAMA Network Open, 2018, 1, e180086.	2.8	4
46	Diagnostic accuracy of pigmented labial macules by inÂvivo reflectance confocal microscopy and correlation among techniques. Journal of the American Academy of Dermatology, 2021, 85, 1151-1160.	0.6	4
47	Fever and pancytopenia in a patient with Crohn's disease. Gut, 2013, 62, 1327-1327.	6.1	3
48	Estimating the potential impact of interventions to reduce overâ€calling and underâ€calling of melanoma. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1519-1527.	1.3	3
49	Comprehensive molecular profiling of metastatic melanoma to predict response to monotherapy and combination immunotherapy Journal of Clinical Oncology, 2019, 37, 9511-9511.	0.8	3
50	BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. Pathology, 2022, 54, 6-19.	0.3	3
51	Effective maybe, but is it costâ€effective? A reply. Histopathology, 2014, 65, 729-730.	1.6	2
52	When is surgery for metastatic melanoma still the most appropriate treatment option?. Expert Review of Anticancer Therapy, 2018, 18, 943-945.	1.1	2
53	Basal cell carcinoma of the palm: An unusual presentation of a common tumour. Australasian Journal of Dermatology, 2020, 61, 69-70.	0.4	2
54	A phase II study of neoadjuvant pembrolizumab and lenvatinib for resectable stage III melanoma: The neopele study Journal of Clinical Oncology, 2020, 38, TPS10088-TPS10088.	0.8	2

#	Article	IF	CITATIONS
55	Proteins Annexin A2 and PSA in Prostate Cancer Biopsies Do Not Predict Biochemical Failure. Anticancer Research, 2017, 37, 6943-6946.	0.5	1
56	Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre. Pathology, 2022, , .	0.3	1
57	Neoadjuvant dabrafenib and trametinib (D+T) for stage III melanoma: Long-term results from the NeoCombi trial Journal of Clinical Oncology, 2022, 40, 9580-9580.	0.8	1
58	Rýcktitelbild: Simple Synthesis and Functionalization of Iron Nanoparticles for Magnetic Resonance Imaging (Angew. Chem. 18/2011). Angewandte Chemie, 2011, 123, 4110-4110.	1.6	0
59	Back Cover: Simple Synthesis and Functionalization of Iron Nanoparticles for Magnetic Resonance Imaging (Angew. Chem. Int. Ed. 18/2011). Angewandte Chemie - International Edition, 2011, 50, 4024-4024.	7.2	0
60	Journal Watch: our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of melanoma management. Melanoma Management, 2019, 6, MMT18.	0.1	0
61	12. A rare skin rash associated with viral infection in the immunosuppressed: A case of trichodysplasia spinulosa. Pathology, 2020, 52, S137.	0.3	0
62	Mutational analysis of undifferentiated melanoma. Pathology, 2020, 52, S63.	0.3	0
63	Genomic alterations in metastatic basal cell carcinoma. Pathology, 2020, 52, S63.	0.3	0
64	Benign blue naevi involving lymph nodes: A case series with accompanying molecular data and long term follow-up confirms clinical behaviour. Pathology, 2020, 52, S70.	0.3	0
65	Assessment of the prognostic role of regression in primary cutaneous melanoma. Pathology, 2020, 52, S64.	0.3	0
66	Intranuclear inclusions are a distinguishing morphological feature of renal cell carcinoma with leiomyomatous stroma. Pathology, 2021, 53, 543-545.	0.3	0
67	Complex melanoma of the scalp: Diagnosis and management aided by confocal microscopy.  Australasian Journal of Dermatology, 2021, , .	0.4	O